↑ 薬物リストへ　← 戻る

Salbutamol    (DrugBank: Salbutamol)

9 diseases
告示番号疾患名（ページ内リンク）臨床試験数
3脊髄性筋萎縮症1
11重症筋無力症2
49全身性エリテマトーデス2
85特発性間質性肺炎1
86肺動脈性肺高血圧症2
111先天性ミオパチー1
228閉塞性細気管支炎1
256筋型糖原病1
299嚢胞性線維症3

3. 脊髄性筋萎縮症　［臨床試験数：179，薬物数：102（DrugBank：26），標的遺伝子数：52，標的パスウェイ数：78］
Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 179 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2007-001088-32-IT
(EUCTR)		29/07/200818/07/2008A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY VS. PLACEBO FOR THE EVALUATION OF EFFICACY AND TOLERABILITY OF SALBUTAMOL ADMINISTERED BY ORAL ROUTE IN PATIENTS AFFECTED BY SPINAL MUSCULAR ATHROPHY. - NDA PHASE II RANDOMIZED, DOUBLE-BLIND STUDY VS. PLACEBO FOR THE EVALUATION OF EFFICACY AND TOLERABILITY OF SALBUTAMOL ADMINISTERED BY ORAL ROUTE IN PATIENTS AFFECTED BY SPINAL MUSCULAR ATHROPHY. - ND Patients affected by SMA
MedDRA version: 9.1;Level: LLT;Classification code 10041582;Term: Spinal muscular atrophy		Trade Name: VOLMAX*30CPR 4MG R.P.
INN or Proposed INN: Salbutamol		ISTITUTO NEUROLOGICO CARLO BESTANULLNot RecruitingFemale: yes
Male: yes		Phase 2Italy

11. 重症筋無力症　［臨床試験数：226，薬物数：172（DrugBank：45），標的遺伝子数：43，標的パスウェイ数：118］
Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 226 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03914638
(ClinicalTrials.gov)		April 1, 201911/4/2019Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia GravisBeta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia GravisMyasthenia GravisDrug: Salbutamol 4Mg Tablet;Drug: Placebo oral capsuleUniversity of AarhusNULLRecruiting18 YearsN/AAll30Phase 2;Phase 3Denmark
2EUCTR2019-000895-40-DK
(EUCTR)		28/03/201926/02/2019Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia GravisBeta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis - BETA-MG Myasthenia Gravis
MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Trade Name: Salbutamol WZF 4 mg
INN or Proposed INN: Salbutamol
Other descriptive name: SALBUTAMOL SULFATE PH. EUR.		Aarhus University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Phase 3Denmark

49. 全身性エリテマトーデス　［臨床試験数：827，薬物数：638（DrugBank：168），標的遺伝子数：108，標的パスウェイ数：191］
Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 827 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2007-004635-29-DK
(EUCTR)		09/11/200702/10/2007Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.Product Name: ASF-1096 Cream 0.25%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 0.5%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 1.0%
INN or Proposed INN: R-salbutamol sulphate		Astion Pharma A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		140Denmark;Spain;Sweden
2EUCTR2007-004635-29-SE
(EUCTR)		07/11/200712/09/2007Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.Product Name: ASF-1096 Cream 0.25%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 0.5%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 1.0%
INN or Proposed INN: R-salbutamol sulphate		Astion Pharma A/SNULLNot RecruitingFemale: yes
Male: yes		140Denmark;Spain;Sweden

85. 特発性間質性肺炎　［臨床試験数：514，薬物数：377（DrugBank：108），標的遺伝子数：97，標的パスウェイ数：204］
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01457261
(ClinicalTrials.gov)		April 201219/10/2011IPF Drug Deposition StudyA Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)Idiopathic Pulmonary FibrosisDrug: SalbutamolRoyal Brompton & Harefield NHS Foundation TrustGlaxoSmithKlineCompleted40 YearsN/ABoth10Phase 1United Kingdom

86. 肺動脈性肺高血圧症　［臨床試験数：1,083，薬物数：667（DrugBank：122），標的遺伝子数：98，標的パスウェイ数：185］
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,083 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02782052
(ClinicalTrials.gov)		July 201617/5/2016Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial HypertensionBronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Nebulized ipratropium bromide;Drug: Nebulized combination ipratropium bromide with salbutamol;Drug: Nebulized PlaceboAssistance Publique - Hôpitaux de ParisNULLWithdrawn18 YearsN/AAll0Phase 3NULL
2EUCTR2014-002590-10-FR
(EUCTR)		11/02/201602/03/2016Effect of bronchodilators on effort induced dyspnoea in lung hypertension patientsEffect of bronchodilators on effort induced dyspnoea in patients suffering lung hypertension - BD-HTAP Idiopathic or heritable patients with pulmonary arterial hypertension (PAH).
MedDRA version: 18.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]		Trade Name: Bromure d'Ipratropium
Product Name: Bromure d'Ipratropium
INN or Proposed INN: Bromure d'Ipratropium
Trade Name: Salbutamol
Product Name: Salbutamol
INN or Proposed INN: Salbutamol		ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes		18Phase 3France

111. 先天性ミオパチー　［臨床試験数：7，薬物数：13（DrugBank：4），標的遺伝子数：1，標的パスウェイ数：8］
Searched query = "Congenital myopathy", "Nemaline myopathy", "Central core disease", "Minicore myopathy", "Myotubular myopathy", "Centronuclear myopathy", "Congenital fiber-type disproportion myopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 7 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-001147-51-SE
(EUCTR)		31/03/202027/09/2019This is a treatment study for a muscle disorder known as congenital myopathyCongenital myopathy intervention study - COMPIS Congenital myopathy
MedDRA version: 20.0;Level: PT;Classification code 10062547;Term: Congenital myopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Trade Name: Ventoline tablet 2mg
INN or Proposed INN: SALBUTAMOL SULFATE
Trade Name: Ventoline oral solution 0,4mg/ml
INN or Proposed INN: SALBUTAMOL SULFATE		Västra götalandsregionenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 4Sweden

228. 閉塞性細気管支炎　［臨床試験数：92，薬物数：125（DrugBank：34），標的遺伝子数：33，標的パスウェイ数：152］
Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 92 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02863835
(ClinicalTrials.gov)		April 20164/5/2016Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants RecipientsEvaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants RecipientsTransplantation, Heart-Lung;Chronic Lung Allograft Dysfunction;Bronchiolitis Obliterans SyndromeOther: EIT;Other: Salbutamol nebulisation and with CPAPGuy's and St Thomas' NHS Foundation TrustADIR AssociationCompleted18 Years70 YearsAll50N/AUnited Kingdom

256. 筋型糖原病　［臨床試験数：161，薬物数：114（DrugBank：23），標的遺伝子数：26，標的パスウェイ数：106］
Searched query = "Muscle glycogenosis", "Muscular glycogenosis", "Muscle glycogen storage disease", "Muscular glycogen storage disease", "Glycogen storage disease type 0", "GSD0", "Glycogen synthase deficiency", "Glycogen storage disease type II", "GSDII", "Pompe disease", "Alpha-1,4-glucosidase acid deficiency", "Glycogen storage disease type III", "GSDIII", "Cori disease", "Glycogen debranching enzyme deficiency", "Glycogen storage disease type IV", "GSDIV", "Andersen disease", "Glycogen-branching enzyme deficiency", "GBED", "Glycogen storage disease type V", "GSDV", "McArdle disease", "Muscle phosphorylase deficiency", "Muscular phosphorylase deficiency", "Glycogen storage disease type VII", "GSDVII", "Tarui disease", "Phosphofructokinase deficiency", "PFK deficiency", "Glycogen storage disease type IX", "GSDIX", "Phosphorylase kinase deficiency", "Phosphoglycerate kinase deficiency", "PGK deficiency", "Glycogen storage disease type X", "GSDX", "Phosphoglycerate mutase deficiency", "Glycogen storage diseass type XI", "GSDXI", "Kanno disease", "Lactate dehydrogenase deficiency", "Glycogen storage diseass type XII", "GSDXII", "Aldolase A deficiency", "Glycogen storage diseass type XIII", "GSDXIII", "Beta-enolase deficiency", "Glycogen storage diseass type XIV", "GSDXIV", "Phosphoglucomutase deficiency", "Glycogen storage diseass type XV", "GSDXV", "Glycogenin 1 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 161 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02405598
(ClinicalTrials.gov)		October 201322/3/2015Evaluation of Salbutamol as an Adjuvant Therapy for Pompe DiseaseEvaluation of Salbutamol as an Adjuvant Therapy for Pompe DiseasePompe DiseaseDrug: SalbutamolNational Taiwan University HospitalNULLCompleted2 YearsN/ABoth14Phase 4Taiwan

299. 嚢胞性線維症　［臨床試験数：1,592，薬物数：1,539（DrugBank：255），標的遺伝子数：81，標的パスウェイ数：162］
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 1,592 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03522831
(ClinicalTrials.gov)		May 1, 201819/3/2018CF BronchodilationA Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic FibrosisLung Diseases;Cystic FibrosisDrug: Salbutamol;Drug: PlaceboUniversity of British ColumbiaNULLRecruiting19 YearsN/AAll20N/ACanada
2EUCTR2015-001317-28-NL
(EUCTR)		30/07/201519/05/2015A B2-agonist as a CFTR activator in CF - Part 2A B2-agonist as a CFTR activator in CF - Part 2 - ABBA 2 Cystic fibrosis;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SalbutamolUMC UtrechtNULLNot RecruitingFemale: yes
Male: yes		Phase 2Netherlands
3EUCTR2014-000057-37-NL
(EUCTR)		30/04/201412/02/2014Bronchodilcation as a CFTR activator in CFA B2-agonist as a CFTR activator in CF - ABBA study Cystic Fibrosis;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]Product Name: Salbutamol
Product Code: R03AC02
INN or Proposed INN: SALBUTAMOL
Product Name: Salbutamol
Product Code: R03CC02
INN or Proposed INN: SALBUTAMOL		University Medical Centre UtrechtNULLNot RecruitingFemale: yes
Male: yes		Phase 2Netherlands

先頭へ